SecBot SecBot

KYMR

Kymera Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001815442 Biotech & Drug Discovery
$125.85 −1.72 (−1.35%)
Nov 16 4:00 PM ET · prev $127.57
Market cap
$10.9B
Large cap
Consensus
Buy
90% Buy or better · 30 analysts
Median target
$144.00
+14% · range $116.00–180.00
1 year
+96.3%
from $64.10 · Nov 17
30 days
+16.5%
from $108.07
52-week range
$64.10–138.86
−9% from high · low Nov 17
Avg volume 20D
1.00M
shares / day
Short interest
8.40M
≈9.8% of shares · −8.4%
Days to cover
10.5
at average volume
Insider net
−$39.5M
0 buyers · 5 sellers · since Jun 29
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
32
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $39.5M.

  • InstitutionsBULLISH

    Q3 2026: 31 added (3 new), 10 trimmed or exited. Largest new: Capital World Investors $24.9M, Fiera Capital $13.3M.

  • AnalystsBULLISH

    27 of 30 rate it Buy or better. Median target $144.00 (+14%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.029 → −$1.286 over 90 days. 4 up, 6 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.4% to 8.40M shares. 10.5 days to cover, ≈9.8% of shares.

  • TrendUPTREND

    7% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$38.2M
in new stakes · top 2 shown
FundMoveSharesValue
MORGAN STANLEYADD359,192$40.2M
Fisher Asset Management, LLCDOUBLED323,219$36.1M
Connor, Clark & Lunn Investment Management Ltd.ADD233,521$26.1M
Capital World InvestorsNEW222,984$24.9M
CITIGROUP INCADD126,813$14.2M
Fiera Capital CorpNEW118,933$13.3M
FIRST TRUST ADVISORS LPADD113,943$12.7M
Invesco Ltd.ADD102,581$11.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

30 analysts
Buy 90% rate it Buy or better
Strong Buy11Buy16Hold3Sell0Strong Sell0
12-month targets · 23 analysts

Price is inside the target range. Median implies +14%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 30, 2026Truist Securities
REITERATE
REITERATEBuy
Oct 30, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 29, 2026BTIG
MAINTAIN
MAINTAINBuy
Oct 27, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 9, 2026Raymond James
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$39.5M
sold · 5 insiders
DateInsiderTypeValue
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$869.8K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$949.7K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$619.0K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$392.8K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
EXERCISE$62.4K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$552.2K
Oct 1, 2026
Mainolfi Nello
Chief Executive Officer
Oct 1, 2026
SELL$30.4K
Sep 4, 2026
Adams Brian
Chief Legal Officer
Sep 4, 2026
SELL$139.7K

Earnings setup

Estimates
−$1.29
EPS estimate, this quarter
−25%
estimate change, 90 days
4↑ 6↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.29-$1.54–-$0.78-0.9%$62.5K
Next Q-$1.35-$1.52–-$1.08+0.9%$7.0M
Current FY🔒 Fresh data, subscribers only
Next FY-$5.12-$6.70–-$3.36-0.4%$42.0M

Short side

FINRA· Oct 30, 2026
8,400,784
shares short
-8.4%
vs prior settlement
10.5
days to cover
≈9.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 2, 2026 SEC
Five institutional asset managers added to their Kymera Therapeutics positions in Q3 2026, with aggregate buying of…
INST-CLUSTER · Impact 3/10
Oct 29, 2026 SEC
Kymera Therapeutics reported Q3 2026 results with no collaboration revenue ($0 vs $2.8M in Q3 2025) and a net loss of…
8-K · Impact 5/10
Oct 29, 2026 SEC
Kymera reported Q3 2026 net loss of $132.0M ($1.32 per share) vs. consensus EPS of -$1.27, a miss. Revenue was $0 (no…
PRESS-RELEASE · Impact 5/10
Oct 29, 2026 Earnings
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust m
Oct 28, 2026 Press
Kymera Therapeutics announced it will present Phase 1 clinical trial results for KT-579, a first-in-class oral IRF5…
Impact 5/10
Oct 1, 2026 Insider
Mainolfi Nello sold 7,601 shares
Chief Executive Officer @ $114.43 ($869.8K)
Oct 1, 2026 Insider
Mainolfi Nello sold 8,230 shares
Chief Executive Officer @ $115.40 ($949.7K)
Oct 1, 2026 Insider
Mainolfi Nello sold 5,506 shares
Chief Executive Officer @ $112.42 ($619.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

32 filings · 5 press releases · 2 bullish · 10 bearish · 2 mixed · 18 neutral
All KYMR filing & press-release reports (37)